Inactive Instrument

Protalix Biotherapeutics Inc Stock price TEL AVIV STOCK EXCHANGE

Equities

US74365A1016

Biotechnology & Medical Research

Sales 2024 * 74.06M 27.09B Sales 2025 * 127M 46.59B Capitalization 92.05M 33.67B
Net income 2024 * 17M 6.22B Net income 2025 * 70M 25.61B EV / Sales 2024 * 1.24 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.72 x
P/E ratio 2024 *
6 x
P/E ratio 2025 *
1.56 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.23%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Protalix Biotherapeutics Inc

Managers TitleAgeSince
Chief Executive Officer 57 19-06-29
Director of Finance/CFO 48 19-07-21
Chief Tech/Sci/R&D Officer 41 20-07-04
Members of the board TitleAgeSince
Director/Board Member 67 19-11-30
Director/Board Member 72 19-11-30
Director/Board Member 80 14-10-31
More insiders
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company's ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Protalix BioTherapeutics, Inc.
  4. Stock Protalix Biotherapeutics Inc - TEL AVIV STOCK EXCHANGE